Polyomavirus Infections – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Polyomavirus Infections – Drugs In Development, 2024 report and make more profitable business decisions.
Polyomaviruses, a family of small DNA viruses, pose potential threats to human health. Among them, the BK virus (BKV) and JC virus (JCV) are known to infect humans, with implications for those with weakened immune systems. While these viruses can circulate without symptoms in the general population, immunocompromised individuals face complications. BKV may induce nephropathy or cystitis, particularly in organ transplant recipients. JCV, prevalent with many carrying antibodies, can lead to progressive multifocal leukoencephalopathy (PML), a severe brain disease, in those with compromised immune function.
The Polyomavirus Infections drugs in development market research report provide comprehensive information on the therapeutics under development for Polyomavirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polyomavirus Infections and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Polyomavirus Infections | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 32 molecules, with 24 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Polyomavirus Infections therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Polyomavirus Infections pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Polyomavirus Infections treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AlloVir IncAmgen Inc
Baylor College of Medicine
Belyntic GmbH
Biological E Ltd
Cellevolve Bio
Children's National Hospital
Evrys Bio
Excision BioTherapeutics Inc
George Papanicolaou Hospital
iCELL Biotechnology Co Ltd
Inhibikase Therapeutics Inc
Memo Therapeutics AG
Merck & Co Inc
NeoImmuneTech Inc
Neurimmune Holding AG
New York Medical College
Orthogon Therapeutics LLC
Palisades Therapeutics
Pomona Ricerca SRL
QIMR Berghofer Medical Research Institute
Shenzhen Geno-Immune Medical Institute
SL VaxiGen Inc
SymBio Pharmaceuticals Ltd
University of Texas MD Anderson Cancer Center
University of Wisconsin Madison
VenatoRx Pharmaceuticals Inc
Vera Therapeutics Inc
Via Nova Therapeutics Inc
Vir Biotechnology Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Polyomavirus Infections reports